Want to join the conversation?
$ADSK's R&D expenses rose 1% during 1Q17 vs. 1Q15 primarily due to an increase in stock-based compensation expense as a result of a higher fair market value of awards granted. This was partially offset by a decrease in professional fees. The company expects R&D expense to increase in absolute dollars and as a percentage of net revenue during 2Q17.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$